Recombinant Human Endostatin Market By Product Type (Therapeutic-Grade Recombinant Human Endostatin Injection, Research-Grade Recombinant Human Endostatin Protein); By Application (Advanced and Metastatic Non-Small Cell Lung Cancer, Malignant Pleural and Thoracoabdominal Effusion, Other Solid Tumors, Angiogenesis and Endothelial-Cell Research); By End User (Hospitals and Oncology Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Preclinical and Laboratory Research Facilities); By Distribution Channel (Hospital Procurement and Reimbursement Channels, Direct Research Supply, Laboratory Product Distributors); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Recombinant Human Endostatin Market - China-Centered Therapeutic Demand Defines the Market

The Global Recombinant Human Endostatin Market was valued at USD 0.158 billion in 2025 and is projected to reach USD 0.278 billion by 2032, expanding at a CAGR of 8.4% during 2026–2032, according to Strategic Market Research.

 

Recombinant human endostatin is a targeted anti-angiogenic drug that limits tumor growth by preventing the formation of new blood vessels. It mainly acts on endothelial cells and VEGF-related pathways, promoting cell death and disrupting signals needed for tumor blood-vessel development. It may also improve the structure of tumor vessels, helping chemotherapy and radiotherapy reach cancer cells more effectively.

 

The drug is primarily used with chemotherapy for advanced or metastatic non-small cell lung cancer. Endostar, a commercial form, was approved in China in 2005, commonly in combination with vinorelbine and cisplatin. It is not approved by the US FDA and remains investigational in the United States. Research continues into its use with chemotherapy, radiotherapy, and immunotherapy for other solid tumors, including sarcoma, melanoma, nasopharyngeal cancer, and cervical cancer.

 

Malignant Pleural Effusion (MPE) – High-Need Oncology Support Segment

malignant effusions market was estimated to be valued at approximately USD 5.12 billion in 2025, reflecting the substantial clinical and economic burden associated with fluid accumulation in cancer patients across various tumor types. Over the forecast period, the market is expected to demonstrate steady and sustained expansion, reaching nearly USD 7.45 billion by 2032. This growth trajectory corresponds to a compound annual growth rate (CAGR) of 5.5% between 2026 and 2032, driven by increasing cancer prevalence, rising incidence of advanced-stage malignancies, and growing demand for improved palliative and supportive care interventions aimed at managing malignant pleural, peritoneal, and pericardial effusions.

Malignant pleural effusion (MPE) affects 480,000 patients annually across major developed healthcare markets and is associated with a median survival of 3 to 12 months, reflecting advanced-stage cancer progression. The condition is most commonly linked to lung and breast cancers, which together account for the majority of global cases.

In terms of clinical burden, around 15% of all cancer patients develop pleural effusion during disease progression. Survival outcomes remain poor, with median survival generally under one year, reinforcing the need for palliative and supportive care approaches. Lung cancer represents the largest share of cases at 30%–40%, followed by breast cancer at 15%–23%, while lymphomas and gastrointestinal cancers account for the remaining proportion. From a diagnostic standpoint, fluid cytology demonstrates a detection rate of approximately 40% on first aspiration, whereas thoracoscopy can achieve diagnostic accuracy of up to 95%, making it a more definitive but invasive option.

Treatment demand is primarily driven by the recurrent nature of effusion, which necessitates repeated hospital visits for fluid drainage and intrapleural interventions. This cycle of recurrence creates sustained reliance on hospital-based oncology services and ongoing supportive care, contributing to a consistent procedural and therapeutic workload in advanced cancer management.

 

Immunotherapy – Expanding but Uneven Response Landscape

Cancer Immunotherapy Market was valued at USD 145.80 billion in 2025 and is projected to reach USD 266.53 billion by 2032, expanding at a CAGR of 9.0% during 2026–2032. This strong growth trajectory reflects the rapid shift in oncology treatment paradigms toward immune-based therapies that harness the body’s own immune system to recognize and destroy cancer cells. Increasing clinical success of immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines has significantly expanded the therapeutic scope of immunotherapy across multiple tumor types, including lung cancer, melanoma, hematologic malignancies, and emerging solid tumor indications. Rising global cancer incidence, coupled with improved diagnostic rates and earlier treatment initiation, is further accelerating demand for advanced and durable treatment options beyond conventional chemotherapy and radiation. In addition, continuous pipeline expansion, growing regulatory approvals across major markets, and increasing integration of immunotherapy into first-line treatment regimens are strengthening market penetration. Supportive reimbursement frameworks in developed economies and expanding access in emerging regions are also contributing to broader adoption. Collectively, these factors are expected to sustain robust market expansion throughout the forecast period.

Cancer immunotherapy has become a major treatment pillar, with over 150 FDA approvals since 2011. However, response rates remain highly variable across tumor types and patient populations, reflecting significant differences in tumor biology, immune microenvironment, and biomarker expression.

Overall, the general response rate across solid tumors ranges from approximately 20% to 40%, with outcomes strongly influenced by whether therapies are used as monotherapy or in combination regimens. High-response cancers such as melanoma and select lung cancers demonstrate response rates or long-term survival benefits of around 35% to 58% when combination therapies are applied, particularly those involving immune checkpoint inhibitors. In contrast, low-response cancers, including microsatellite-stable (MSS) tumors and other resistant solid tumors, often show limited clinical benefit when treated with immunotherapy alone, highlighting the need for combination approaches or alternative therapeutic strategies.

In specific clinical settings, advanced non-small cell lung cancer (NSCLC) has shown meaningful survival improvements with agents such as pembrolizumab, where 5-year survival rates have increased from approximately 5.5% to 15%–23%, depending on PD-L1 expression levels. In hematologic malignancies, CAR-T cell therapies have demonstrated high efficacy, achieving around 58% complete remission rates in relapsed diffuse large B-cell lymphoma (DLBCL), representing one of the most significant advances in refractory blood cancer treatment. Reflecting broader clinical adoption, real-world use of immunotherapy has expanded dramatically, increasing nearly 20-fold since 2011 as indications, approvals, and physician familiarity have grown.

Overall, immunotherapy continues to expand its role in oncology, with global treatment use now spanning more than 20 cancer types and subtypes. However, its effectiveness remains highly dependent on biomarkers, tumor type, and combination treatment strategies, resulting in uneven global adoption and variable patient outcomes across different cancer indications.

 

Chemotherapy – Broad Utilization Across Cancer Care Pathways

Cancer Chemotherapy Market was valued at USD 52.40 billion in 2025 and is projected to reach USD 85.25 billion by 2032, expanding at a CAGR of 7.2% during 2026–2032. This steady growth reflects the rising global cancer burden, increasing adoption of combination chemotherapy regimens, and continued reliance on cytotoxic drugs as a backbone of cancer treatment across multiple tumor types. Despite the rapid expansion of targeted therapies and immuno-oncology drugs, chemotherapy remains a foundational treatment option, particularly in low- and middle-income countries where access to advanced biologics is limited. The market expansion is further supported by ongoing clinical research aimed at improving drug efficacy, reducing toxicity, and optimizing treatment protocols, as well as the growing number of hospital admissions requiring systemic cancer therapy worldwide.

Chemotherapy remains one of the most widely used cancer treatment modalities, administered to an estimated 25% to 50% of all cancer patients globally during their treatment journey. It continues to play a central role in oncology care due to its broad applicability across multiple cancer types and stages, especially in regions where access to advanced targeted or immunotherapy options is limited. Chemotherapy is frequently used in combination with surgery, radiation therapy, targeted agents, or immunotherapy to improve overall treatment outcomes and reduce the risk of disease progression or recurrence. It remains essential in both curative treatment settings and palliative care, where the focus is on extending survival and improving quality of life.

Globally, chemotherapy is used in a large proportion of major cancer indications, including breast, lung, colorectal, ovarian, and blood cancers. In breast cancer alone, more than 2.3 million new cases are diagnosed annually worldwide, and chemotherapy is recommended in a significant share of moderate- to high-risk patients. In lung cancer, which accounts for about 2.5 million new cases each year, chemotherapy continues to be widely used, particularly in advanced non-small cell lung cancer where targeted mutations are not present. Colorectal cancer, with over 1.9 million new cases annually, also relies heavily on chemotherapy-based regimens as part of standard treatment protocols.

In terms of clinical outcomes, chemotherapy contributes meaningfully to survival improvement across several cancer types. For example, testicular cancer shows one of the highest success rates in oncology, with approximately 95% to 99% five-year survival when treated using multi-modal approaches that include chemotherapy. In breast cancer, chemotherapy has been shown to reduce recurrence risk by 30% to 50% in high-risk patients depending on tumor subtype and stage. In colorectal cancer, adjuvant chemotherapy can improve five-year survival by approximately 10% to 15% in stage III disease. In contrast, for advanced metastatic cancers, chemotherapy generally provides more modest benefits, with median survival improvements often ranging from a few months to over a year, depending on cancer type and treatment combination, while still offering meaningful symptom control and disease stabilization.

From a market perspective, chemotherapy continues to function as a foundational pillar of cancer treatment despite the rapid growth of targeted therapies and immuno-oncology drugs. It remains widely accessible across both developed and emerging healthcare systems, supported by established treatment guidelines and reimbursement frameworks. The large and continuously growing global cancer burden, combined with its use across multiple lines of therapy, ensures that chemotherapy retains a stable and essential role in oncology practice worldwide.

 

Non-Small Cell Lung Cancer (NSCLC) – Largest Lung Cancer Subtype Driving Treatment Demand

Established NSCLC Therapeutics Market was valued at USD 35.60 billion in 2025 and is projected to reach USD 56.42 billion by 2032, expanding at a CAGR of 6.8% during 2026–2032. This growth reflects the sustained global burden of non-small cell lung cancer, which continues to be the most prevalent subtype of lung cancer and a leading cause of cancer-related mortality worldwide. Increasing adoption of advanced treatment modalities, including targeted therapies, immune-checkpoint inhibitors, and combination regimens with chemotherapy, is driving steady expansion of the treatment landscape. In addition, improvements in early diagnosis, biomarker testing, and personalized medicine approaches are contributing to higher treatment uptake and longer therapy duration per patient. The market is further supported by ongoing clinical research aimed at improving survival outcomes in advanced and metastatic disease settings, where unmet medical need remains significant despite recent therapeutic advances.

NSCLC represents approximately 80% to 85% of all lung cancer cases globally, making it the dominant driver of lung cancer treatment demand. In terms of survival outcomes, patients diagnosed at a localized stage have a 5-year survival rate of around 60%–65%, while those with regional spread show significantly lower survival at approximately 34%–37%. For patients diagnosed with distant metastasis, outcomes remain poor, with a 5-year survival rate of only about 9%–10%, reflecting the high unmet need in advanced disease management.

From a market perspective, NSCLC accounts for the largest share of lung cancer treatment spending worldwide, supported by an estimated 2+ million new lung cancer cases annually, of which the majority are NSCLC. The disease is most frequently diagnosed in patients aged 65–75 years, aligning with aging population trends in both developed and emerging markets. Adenocarcinoma and squamous cell carcinoma remain the most common subtypes, together representing over 85% of NSCLC cases, which directly shapes treatment protocols and drug utilization patterns.

Tobacco smoking continues to be the leading risk factor, contributing to a significant portion of global incidence, although rising cases among non-smokers—particularly adenocarcinoma—are increasingly observed in urban populations and women in parts of Asia.

Overall, NSCLC remains the largest commercial treatment segment within oncology, driving sustained demand across chemotherapy, targeted therapies, immunotherapy, and combination regimens. Its high incidence, frequent late-stage diagnosis, and need for long-term disease management continue to support strong and recurring treatment utilization across global healthcare systems.

 

China Leads Therapeutic Revenue While Other Regions Remain Research-Oriented

China accounts for the established therapeutic market because Endostar is approved, reimbursed, and included in oncology practice. Simcere identifies it as the only approved endostatin product worldwide and reports its use as a cornerstone treatment for advanced NSCLC in China.

Therapeutic expansion into the United States, Europe, and other regulated markets would require region-specific clinical trials, manufacturing documentation, regulatory submissions, and comparative evidence against existing anti-angiogenic drugs.

The presence of endostatin in scientific literature or laboratory catalogs does not represent therapeutic approval or hospital adoption.

Outside China, visible market activity is concentrated in recombinant proteins supplied for research. Thermo Fisher Scientific’s PeproTech product is an E. coli-expressed 20.2 kDa protein with reported purity of at least 98%. Its biological activity is measured through inhibition of endothelial-cell migration, and it is restricted to research use.

Sigma-Aldrich also provides an E. coli-expressed recombinant human endostatin product with assay purity above 98%. Leinco Technologies offers a research-grade version with purity above 95% and an endotoxin level below 0.01 EU per microgram.

These products are used in angiogenesis assays, endothelial-cell studies, and preclinical cancer research. They are not substitutes for sterile clinical-grade Endostar injection.

The therapeutic and research-use segments should therefore be measured separately. Clinical revenue depends on treatment cycles, reimbursement, and hospital use. Research demand is shaped by laboratory budgets, publication activity, assay development, and the need for consistent protein quality.

 

Market Drivers and Trends

Established Oncology Applications

Recombinant human endostatin has gained clinical acceptance in China, particularly as part of combination treatment regimens for advanced non-small cell lung cancer and other solid tumors.

Research into New Therapeutic Areas

Continued investigation into angiogenesis-related disorders may broaden its potential use beyond oncology, including conditions such as fibrosis and atherosclerosis.

Development of Improved Recombinant Products

Manufacturers and researchers are working on next-generation variants with greater molecular stability, longer half-life, and improved pharmacokinetic performance to support wider international adoption.

 

Market Challenges

Dependence on the Chinese Market

Commercial demand for recombinant human endostatin remains highly concentrated in China, while regulatory approval and clinical adoption in other major markets remain limited.

Competition from Advanced Cancer Therapies

The market faces strong competition from widely adopted anti-angiogenic agents, molecularly targeted drugs, and immune-checkpoint inhibitors with broader global availability and stronger clinical recognition.

 

Major Companies and Competitive Positioning

Simcere Pharmaceutical Group and Simcere Zaiming hold the dominant therapeutic position through Endostar. Their advantage extends beyond ownership of the approved product.

Simcere reported coverage of more than 3,600 Class III hospitals and approximately 17,000 other hospitals and medical institutions in China at the end of 2025. This network supports oncology promotion, reimbursement access, and distribution across provincial markets.

Simcere’s anti-oncology revenue increased from RMB 1.298 billion in 2024 to RMB 1.987 billion in 2025, representing growth of 53.0%.

This figure includes the company’s wider oncology portfolio and possible licensing income, so it should not be treated as Endostar revenue. It nevertheless shows that the company has an expanding oncology platform capable of supporting clinical development, manufacturing, and hospital access.

Thermo Fisher Scientific, Sigma-Aldrich, and Leinco Technologies operate in the research-use segment. Their products compete through purity, endotoxin control, biological activity, batch documentation, pack size, and distribution coverage.

These companies enable preclinical and academic research but do not compete directly with Simcere for clinical prescriptions.

Within hospitals, Endostar’s main competition comes from other anti-angiogenic agents, targeted treatments, and immunotherapy combinations rather than from another recombinant endostatin brand.

Its position depends on whether it improves outcomes enough to justify additional infusion time, treatment cost, and clinical complexity.

 

Analyst Perspective

The recombinant human endostatin market is projected to grow from USD 0.158 billion in 2025 to USD 0.278 billion by 2032 at a CAGR of 8.4%. The forecast reflects a specialized oncology market with a strong Chinese treatment base and limited therapeutic adoption elsewhere.

The thoracoabdominal-effusion application is the most immediate regulatory catalyst because it creates a new treatment episode beyond systemic NSCLC therapy.

Immunotherapy combinations provide the larger long-term opportunity, but they face a higher evidence threshold. Endostar must show added survival or disease-control benefit against treatment regimens that already include effective PD-1 or PD-L1 inhibitors.

The market remains concentrated because Simcere has the only approved therapeutic product and an established Chinese hospital network. Research-grade protein companies broaden scientific access but contribute to a separate, lower-value segment.

Combining therapeutic injection sales with laboratory reagents would overstate direct competition and the size of the treated patient market.
 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.158 Billion
Revenue Forecast in 2032	USD 0.278 Billion
Overall Growth Rate	CAGR of 8.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Distribution Channel, By Geography
By Product Type	Therapeutic-Grade Recombinant Human Endostatin Injection, Research-Grade Recombinant Human Endostatin Protein
By Application	Advanced and Metastatic Non-Small Cell Lung Cancer, Malignant Pleural and Thoracoabdominal Effusion, Other Solid Tumors, Angiogenesis and Endothelial-Cell Research
By End User	Hospitals and Oncology Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Preclinical and Laboratory Research Facilities
By Distribution Channel	Hospital Procurement and Reimbursement Channels, Direct Research Supply, Laboratory Product Distributors
By Region	China, North America, Europe, Asia-Pacific Excluding China, Latin America, Middle East and Africa
Country Scope	China, U.S., Canada, UK, Germany, France, Italy, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Approved and reimbursed use of Endostar in China; sustained treatment demand in advanced NSCLC; investigation of combination regimens involving chemotherapy, radiotherapy, and immunotherapy; potential expansion in malignant pleural and thoracoabdominal effusion management; continued laboratory demand for high-purity recombinant endostatin proteins
Customization Option	Available upon request